DEADLINE ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against HeartWare International I...

Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against HeartWare International Inc. (“HeartWare” or the “Company”) (Nasdaq: HTWR). Investors who purchased or otherwise acquired shares between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”) are encouraged to contact the Firm prior to the March 22, 2016 lead plaintiff motion deadline.

If you purchased shares of HeartWare during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: [phone], or by email at [e-mail].

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the U.S. Food and Drug Administration (FDA) issued a Warning Letter identifying several regulatory failures at the Company's sole manufacturing facility. The Company had falsely assured the investing public that those issues had been remedied, and claimed that those issues posed no threat to the approval of MVAD.

If you purchased shares of HeartWare during the Class Period, you have until March 22, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: [phone], or by email at [e-mail].

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208006373/en/

KHANG & KHANG LLPJoon M. Khang, Esq.Telephone: [phone]Facsimile: [e-mail]